Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib

NCT04770688 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Non-Small Cell Lung Cancer With EGFR Mutation
Locally Advanced Solid Tumor
Metastatic Cancer
Adenocarcinoma of Lung

Interventions

DRUG: Osimertinib
DRUG: Anlotinib

Sponsor

Shanghai Chest Hospital